See every side of every news story
Published loading...Updated

EU Commission fines Teva $500 million for trying to stop rival’s multiple sclerosis drug

  • The European Commission fined Teva more than 460 million euros, or $500 million, for improperly seeking to protect its multiple sclerosis drug patent and disparaging a rival's competing medicine.
  • Teva used a "disparagement campaign" against Synthon, which had an authorized glatiramer acetate drug, to "sow doubt on the safety, efficacy and therapeutic equivalence" of the rival product.
  • Teva disagreed with the decision, claiming it was based on "legal theories... That are extreme, untested, and factually unsupported," and must pay the fine and avoid similar actions.
Insights by Ground AI
Does this summary seem wrong?

26 Articles

All
Left
9
Center
4
Right
3
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • 56% of the sources lean Left
56% Left
Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

U.S. News broke the news in New York, United States on Thursday, October 31, 2024.
Sources are mostly out of (0)

You have read out of your 5 free daily articles.

Join us as a member to unlock exclusive access to diverse content.